On July 27, Hims & Hers Health Inc. rose 5.5% in regular trading, trading at $29.17/share, with turnover of $79.55 million.

On the news front, the FDA advisory committee recently voted to include the Bpc-157 peptide on the list of substances permitted for pharmacy compounding, delivering a positive regulatory signal. The company had previously actively advocated at panel meetings for the FDA to expand access to specific peptide drugs. This decision is expected to broaden the prescription drug coverage of the company's telehealth platform and create incremental growth opportunities for its GLP-1 weight management business.

Additionally, multiple institutions have recently raised their price targets on the stock. BofA Securities adjusted its target to $36 from $25 while maintaining a neutral rating, and Truist raised its target to $27 from $23, keeping a hold rating. The average analyst price target stands at approximately $30.69 according to FactSet.

Hims & Hers Health Inc. operates a multi-specialty telehealth platform connecting consumers with licensed healthcare professionals across mental health, sexual health, dermatology, and primary care.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)